A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial With an Open-Label Extension Phase of Perampanel as Adjunctive Treatment in Subjects at Least 2 Years of Age With Inadequately Controlled Seizures Associated With Lennox-Gastaut Syndrome
Phase of Trial: Phase III
Latest Information Update: 13 Jul 2017
At a glance
- Drugs Perampanel (Primary)
- Indications Lennox-Gastaut syndrome
- Focus Adverse reactions; Therapeutic Use
- Sponsors Eisai Inc
- 15 Mar 2017 Planned End Date changed from 1 Aug 2020 to 1 Feb 2020.
- 15 Mar 2017 Planned primary completion date changed from 1 Aug 2019 to 1 Feb 2019.
- 28 Oct 2016 Status changed from not yet recruiting to recruiting, as per Eisai media release.